Pharmacological Efficacy/Toxicity of Drugs: A Comprehensive Update About the Dynamic Interplay of Microbes

Journal of Pharmaceutical Sciences

Volumn 107, Issue 3, 2018, Pages 778-784

  Gimenez Bastida, Juan Antonio ^a   Martinez Carreras, Lucia ^b   Moya Pérez, Angela ^c   Laparra Llopis, José Moisés ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IMDEA FOOD INSTITUTE   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Efficacy; Metabolism; Microbes; Therapeutics; Toxicity

Indexed keywords

CLONAZEPAM; DIGOXIN; NITRAZEPAM; SALAZOSULFAPYRIDINE; SULFAMIDOCHRYSOIDINE; VALDECOXIB; DRUG;

BACILLUS SUBTILIS; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BACTEROIDES UNIFORMIS; BACTEROIDES VULGATUS; BEAUVERIA BASSIANA; DECARBOXYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG TRANSFORMATION; EGGERTHELLA LENTA; ENVIRONMENTAL FACTOR; IMMUNOTHERAPY; INTESTINE FLORA; MENTAL DISEASE; MICROBIAL METABOLISM; MICROBIOME; NEUROENDOCRINE SYSTEM; NITRATION; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; REVIEW; STOMACH PARESIS; ANIMAL; DRUG EFFECT; GASTROINTESTINAL TRACT; HUMAN; MICROBIOLOGY; MICROFLORA; NEOPLASM;

ANIMALS; GASTROINTESTINAL TRACT; HUMANS; MICROBIOTA; NEOPLASMS; PHARMACEUTICAL PREPARATIONS;

EID: 85034827142     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2017.10.031     Document Type: Review

References (85)

1. Jia, W., Li, H., Zhao, L., Nicholson, J.K., Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov 7:2 (2008), 123–129.
2. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031.
3. Blaut, M., Ecology and physiology of the intestinal tract. Curr Top Microbiol Immunol 358 (2013), 247–272.
4. Nicholson, J.K., Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol, 2, 2006, 52.
5. Tzika, A.A., Constantinou, C., Bandyopadhaya, A., et al. A small volatile bacterial molecule triggers mitocondrial dysfunction in murine skeletal muscle. PLoS One, 8(9), 2013, e74528.
6. Cani, P.D., Delzenne, N.M., The gut microbiome as therapeutic target. Pharmacol Ther 130:2 (2011), 202–212.
7. Sousa, T., Paterson, R., Moore, V., Carlsson, A., Abrahamsson, B., Basit, A.W., The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 363:1-2 (2008), 1–25.
8. Wilson, I.D., Nicholson, J.K., The role of gut microbiota in drug response. Curr Pharm Des 15 (2009), 1519–1523.
9. Carmody, R.N., Turnbaugh, P.J., Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest 124:10 (2014), 4173–4181.
10. Gill, S.R., Pop, M., Deboy, R.T., et al. Metagenomic analysis of the human distal gut microbiome. Science 312:5778 (2006), 1355–1359.
11. Mathan, V.I., Wiederman, J., Dobkin, J.F., Lindenbaum, J., Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. Gut 30:7 (1989), 971–977.
12. Björkholm, B., Bok, C.M., Lundin, A., et al. Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS One, 4(9), 2009, e6958.
13. Davey, K.J., O'Mahony, S.M., Schellekens, H., et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl) 221:1 (2012), 155–169.
14. Qin, X., Gut microbiota: a new aspect that should be taken into more consideration when assessing the toxicity of chemicals or the adverse effects and efficacy of drugs. Regul Toxicol Pharmacol, 51(2), 2008, 251.
15. Li, H., He, J., Jia, W., The influence of gut microbiota on drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 12:1 (2016), 31–40.
16. Kim, D.H., Gut microbiota-mediated drug-antibiotic interactions. Drug Metab Dispos 43:10 (2015), 1581–1589.
17. Meini, W., Sczesny, S., Brigelius-Flohé, R., Blaut, M., Glatt, H., Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic-metabolizing enzymes in rat. Drug Metab Dispos 37:6 (2009), 1179–1186.
18. Moens, E., Veldhoen, M., Epithelial barrier biology; Good fences make good neighbours. Immunology 135:1 (2012), 1–8.
19. Hattori, M., Taylor, T.D., The human intestinal microbiome: a new frontier of human biology. DNA Res 16:1 (2009), 1–12.
20. Zhang, L.S., Davies, S.S., Genome medicine, microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med, 8(1), 2016, 46.
21. Zhou, S.S., Xu, J., Zhu, H., et al. Gut microbiota-involved mechanisms in enhancing systemic exposure of ginsenosides by coexisting polysaccharides in ginseng decoction. Sci Rep, 6, 2016, 22474.
22. Yamamoto, M., Kurita, A., Asahara, T., et al. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep 20:4 (2008), 727–730.
23. Li, F., Hullar, M.A., Beresford, S.A., Lampe, J.W., Variation of glucoraphanin metabolism in vivo and ex vivo by human gut bacteria. Br J Nutr 106 (2011), 408–416.
24. Sekirov, I., Russell, S.L., Antunes, L.C.M., Finlay, B.F., Gut microbiota in health and disease. Physiol Rev 90:3 (2010), 859–904.
25. Koch, R.L., Beaulieu, B.B. Jr., Goldman, P., Role of the intestinal flora in the metabolism of misonidazole. Biochem Pharmacol 29:24 (1980), 3281–3284.
26. Strong, H.A., Renwick, A.G., George, C.F., Liu, Y.F., Hill, M.J., The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Xenobiotica 17:6 (1987), 685–696.
27. Strong, H.A., Renwick, A.G., George, C.F., The site of reduction of sulphinpyrazone in the rabbit. Xenobiotica 14:10 (1984), 815–826.
28. Keshetti, S., Ciddi, V., Biotransformation of valdecoxib by microbial cultures. J Microbiol Biotechnol 20:4 (2010), 809–816.
29. Chrystal, E.J., Koch, R.L., McLafferty, M.A., Goldman, P., Relationship between metronidazole metabolism and bactericidal activity. Antimicrob Agents Chemother 18:4 (1980), 566–573.
30. Kitamura, S., Sugihara, K., Kuwasako, M., Tatsumi, K., The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol 49:3 (1997), 253–256.
31. Elmer, G.W., Remmel, R.P., Role of intestinal microflora in clonazepam metabolism in the rat. Xenobiotica 14 (1984), 829–840.
32. Takeno, S., Sakai, T., Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction. Teratology 44:2 (1991), 209–214.
33. Lee, H.J., Zhang, H., Orlovich, D.A., Fawcett, J.P., The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica 42:8 (2012), 791–797.
34. Hayllar, J., Bjarnason, I., Sulphasalazine in ulcerative colitis: in memoriam?. Gut 32:5 (1991), 462–463.
35. Gustafsson, B.E., Norin, K.E., Development of germ-free animal characteristics in conventional rats in antibiotics. Acta Pathol Microbiol Scand B 85B:1 (1977), 1–8.
36. Basit, A.W., Podczeck, F., Newton, J.M., et al. The use of formulation technology to assess regional gastrointestinal drug absorption in humans. Eur J Pharm Sci 21:2-3 (2004), 179–189.
37. Gramatté, T., el Desoky, E., Klotz, U., Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol 46:3 (1994), 253–259.
38. Watanabe, K., Yamashita, S., Furuno, K., Kawasaki, H., Gomita, Y., Metabolism of omeprazole by gut flora in rats. J Pharm Sci 84:4 (1995), 516–517.
39. Wallace, J.L., Syer, S., Denou, E., et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141:4 (2011), 1314–1322.
40. Ogura, K., Nishiyama, T., Takubo, H., et al. Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine. Cancer Lett 122:1-2 (1998), 107–113.
41. Nakayama, H., Kinouchi, T., Kataoka, K., et al. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 7:1 (1997), 35–43.
42. Sivan, A., Corrales, L., Hubert, N., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 350:6264 (2015), 1084–1089.
43. Alexander, J.L., Wilson, I.D., Teare, J., et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol 14:6 (2017), 356–365.
44. Hwang, B.Y., Oh, J.M., Kim, J., Kim, B.G., Pro-antibiotic substrates for the identification of enantioselective hydrolases. Biotechnol Lett 28:15 (2006), 1181–1185.
45. Karapetkov, N., Georgieva, R., Rumyan, N., Karaivanova, E., Antibiotic susceptibility of different lactic acid bacteria strains. Benef Microbes 2:4 (2011), 335–339.
46. Abu Shamat, M., The role of gastrointestinal microflora in the metabolism of drugs. Int J Pharm 97 (1993), 1–13.
47. Blehert, D.S., Knoke, K.L., Fox, B.G., Chambliss, G.H., Regioselectivity of nitroglycerin denitration by flavoprotein nitroester reductases purified from two Pseudomonas species. J Bacteriol 179 (1997), 6912–6920.
48. Accashian, J.V., Vinopal, R.T., Kim, B.J., Smets, B.F., Aerobic growth on nitroglycerin as the sole carbon, nitrogen, and energy source by a mixed bacterial culture. Appl Environ Microbiol 64:9 (1998), 3300–3304.
49. Lee, S., Chen, Y., Luo, H., et al. The first global screening of protein substrates bearing protein-bound 3,4-Dihydroxyphenylalanine in Escherichia coli and human mitochondria. J Proteome Res 9:11 (2010), 5705–5714.
50. Deloménie, C., Fouix, S., Longuemaux, S., et al. Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol 183:11 (2001), 3417–3427.
51. Corbett, M.D., Wei, C.I., Fernando, S.Y., Doerge, D.R., Corbett, B.R., The synthesis and mutagenicity of the N-formyl analog of N-hydroxyphenacetin. Carcinogenesis 4:12 (1983), 1615–1618.
52. Caldwell, J., Hawksworth, G.M., The demethylation of methamphetamine by intestinal microflora. J Pharm Pharmacol 25:5 (1973), 422–424.
53. Shu, Y.Z., Kingston, D.G., Van Tassell, R.L., Wilkins, T.D., Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria. Xenobiotica 21:6 (1991), 737–750.
54. Meuldermans, W., Hendrickx, J., Mannens, G., et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos 22:1 (1994), 129–138.
55. Schiller, L.R., Evaluation of small bowel bacterial overgrowth. Curr Gastroenterol Rep 9:5 (2007), 373–377.
56. Claus, S.P., Ellero, S.L., Berger, B., et al. Colonization-induced host-gut microbial metabolic interaction. MBio 2:2 (2011), e00271–e002710.
57. Takasuna, K., Hagiwara, T., Hirohashi, M., et al. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:4 (1998), 280–286.
58. Songu-Mize, E., Nash, C.B., Elam, J.T., Caldwell, R.W., Metabolism and cardiac actions of a polar aminocardenolide and digoxin in the conscious dog. J Pharmacol Exp Ther 226:1 (1983), 65–70.
59. Hasegawa, H., Sung, J.H., Matsumiya, S., Uchiyama, M., Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med 62:5 (1996), 453–457.
60. Tawab, M.A., Bahr, U., Karas, M., Wurglics, M., Schubert-Zsilavecz, M., Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 31:8 (2003), 1065–1071.
61. Akao, T., Kawabata, K., Yanagisawa, E., et al. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J Pharm Pharmacol 52:12 (2000), 1563–1568.
62. Kenyon, E.M., Calabrese, E.J., Extent and implications of interspecies differences in the intestinal hydrolysis of certain glucuronideconjugates. Xenobiotica 23:4 (1993), 373–381.
63. Matuskova, Z., Siller, M., Tunkova, A., et al. Effects of Lactobacillus casei on the expression and the activity of cytochromes P450 and on the CYP mRNA level in the intestine and the liver of male rats. Neuro Endocrinol Lett, 32, 2011, S1.
64. Selwyn, F.P., Cui, J.Y., Klaassen, C.D., RNA-seq quantification of hepatic drug processing genes in germ-free mice. Drug Metab Dispos 43 (2015), 1572–1580.
65. Overvik, E., Lindeskop, P., Midtvedt, T., Gustafsson, J.A., Mutagen excretion and cytochrome P-450 dependant activity in germ free and conventional rats fed a diet containing fried meat. Food Chem Toxicol 28 (1990), 253–261.
66. Rowland, I.R., Mallett, A.K., Cole, C.B., Fuller, R., Mutagen activation by hepatic fractions from conventional, germ free and monoassociated rats. Arch Toxicol S11 (1987), 261–263.
67. Muccioli, G.G., Naslain, D., Bäckhed, F., et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol, 6, 2010, 392.
68. Martinez, A., Macheda, T., Morgese, M.G., Trabace, L., Giuffrida, A., The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neurosci Res 72:3 (2012), 236–242.
69. Karwad, M.A., Couch, D.G., Theophilidou, E., et al. The role of CB1 in intestinal permeability and inflammation. FASEB J 31:8 (2017), 3267–3277.
70. Mercado-Lubo, R., McCormick, B.A., The interaction of gut microbes with host ABC transporters. Gut Microbes 1:5 (2010), 301–306.
71. Van Baarlen, P., Troost, F., van der Meer, C., et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci U S A 108 (2011), 4562–4569.
72. Nicholson, J.K., Holmes, E., Lindon, J.C., Wilson, I.D., The challenges of modeling mammalian biocomplexity. Nat Biotechnol 22:10 (2004), 1268–1274.
73. Andrews, C.N., Griffiths, T.A., Kaufman, J., et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 34:3 (2011), 374–383.
74. Wang, J., Ma, J., Charboneau, R., Barke, R., Roy, S., Morphine inhibits murine dendritic cell IL-23 production by modulating Toll-like receptor 2 and Nod2 signaling. J Biol Chem 286:12 (2011), 10225–10232.
75. Eisenstein, T.K., Opioids and the immune system: what is their mechanism of action?. Br J Pharmacol 164:7 (2011), 1826–1828.
76. Koller, M.M., Purushotham, K.R., Maeda, N., Scarpace, P.J., Humphreys-Beher, M.G., Desipramine induced changes in salivary proteins, cultivable oral microbiota and gingival health in aging female NIA Fischer 344 rats. Life Sci 68:4 (2000), 445–455.
77. Macedo, D., Filho, A.J., Soares de Sousa, C.N., et al. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. J Affect Disord 208 (2016), 22–32.
78. Zhang, E.Y., Xiong, J., Parker, B.L., et al. Depletion and recovery of lymphoid subsets following morphine administration. Br J Pharmacol 164 (2001), 1829–1844.
79. Meng, J., Banerjee, S., Li, D., et al. Opioid exacerbation of grampositive sepsis, induced by gut microbial modulation, is rescued by IL-17A neutralization. Sci Rep, 5, 2015, 10918.
80. Meng, J., Sindberg, G.M., Roy, S., Disruption of gut homeostasis by opioids accelerates HIV disease progression. Front Microbiol 6 (2015), 643–654.
81. Gardy, J.L., Johnston, J.C., Ho Sui, S.J., et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 364:8 (2011), 730–739.
82. Garmendia, J., Morey, P., Bengoechea, J.A., Impact of cigarette smoke exposure on host-bacterial pathogen interactions. Eur Respir J 39:2 (2012), 467–477.
83. Mutlu, E., Keshavarzian, A., Engen, P., Forsyth, C.B., Sikaroodi, M., Gillevet, P., Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 33 (2009), 1836–1846.
84. Liu, C., Hu, M., Guo, H., et al. Combined contribution of increased intestinal permeability and inhibited deglycosylation of ginsenoside Rb1 in the intestinal tract to the Enhancement of ginsenoside Rb1 exposure in diabetic rats after oral administration. Drug Metab Dispos 43:11 (2015), 1702–1710.
85. Semenkovich, C.F., Danska, J., Darsow, T., et al. American diabetes association and JDRF research symposium: diabetes and the microbiome. Diabetes 64:12 (2015), 3967–3977.